Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR
- PMID: 17622954
- DOI: 10.1203/PDR.0b013e3181256492
Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR
Abstract
Phytosterols, components of soy-derived lipids, are among the proposed exacerbants of parenteral nutrition-associated cholestasis (PNAC). We investigated whether phytosterols contribute to bile acid (BA)-induced hepatocyte damage by antagonizing a nuclear receptor (NR) critically involved in hepatoprotection from cholestasis, FXR (farnesoid X receptor, NR1H4). In HepG2 cells, stigmasterol acetate (StigAc), a water-soluble Stig derivative, suppressed ligand-activated expression of FXR target genes involved in adaptation to cholestasis (i.e. BSEP, FGF-19, OSTalpha/beta). Furthermore, StigAc antagonized BA-activated, FXR target genes SHP and BSEP in FXR+/+, but not in FXR-/- mouse hepatocytes. Both Stig and StigAc inhibited BA-activated, FXR-dependent reporter gene expression in transfected HepG2 cells, whereas the most prevalent phytosterol in lipids, beta-sitosterol, had no inhibitory effect. Finally, among six ligand-activated NR-ligand binding domains (LBDs) tested, antagonism by StigAc was specific to only two (FXR and PXR, pregnane X receptor, NR1I2). We demonstrate that Stig, a phytosterol prevalent in soy-derived PN lipid solutions, is a potent in vitro antagonist of the NR for bile acids FXR.
Similar articles
-
Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice.Hepatology. 2022 Feb;75(2):252-265. doi: 10.1002/hep.32101. Epub 2021 Dec 7. Hepatology. 2022. PMID: 34387888
-
NF-κB Regulation of LRH-1 and ABCG5/8 Potentiates Phytosterol Role in the Pathogenesis of Parenteral Nutrition-Associated Cholestasis.Hepatology. 2021 Dec;74(6):3284-3300. doi: 10.1002/hep.32071. Epub 2021 Aug 27. Hepatology. 2021. PMID: 34310734 Free PMC article.
-
Bile salt excretory pump: biology and pathobiology.J Pediatr Gastroenterol Nutr. 2006 Jul;43 Suppl 1:S10-6. doi: 10.1097/01.mpg.0000226385.71859.5f. J Pediatr Gastroenterol Nutr. 2006. PMID: 16819395 Review.
-
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.Mol Endocrinol. 2003 Feb;17(2):259-72. doi: 10.1210/me.2002-0120. Mol Endocrinol. 2003. PMID: 12554753
-
FXR, a bile acid receptor and biological sensor.Trends Cardiovasc Med. 2000 Jan;10(1):30-5. doi: 10.1016/s1050-1738(00)00043-8. Trends Cardiovasc Med. 2000. PMID: 11150726 Review.
Cited by
-
Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases.Front Pharmacol. 2020 Aug 26;11:1247. doi: 10.3389/fphar.2020.01247. eCollection 2020. Front Pharmacol. 2020. PMID: 32982723 Free PMC article. Review.
-
Risk of Liver Injury Associated with Intravenous Lipid Emulsions: A Prescription Sequence Symmetry Analysis.Front Pharmacol. 2021 Mar 1;12:589091. doi: 10.3389/fphar.2021.589091. eCollection 2021. Front Pharmacol. 2021. PMID: 33732151 Free PMC article.
-
Mechanisms of Parenteral Nutrition-Associated Liver and Gut Injury.Nutr Clin Pract. 2020 Feb;35(1):63-71. doi: 10.1002/ncp.10461. Epub 2019 Dec 23. Nutr Clin Pract. 2020. PMID: 31872510 Free PMC article. Review.
-
Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added α-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury.Am J Clin Nutr. 2019 Apr 1;109(4):1038-1050. doi: 10.1093/ajcn/nqy370. Am J Clin Nutr. 2019. PMID: 30882140 Free PMC article.
-
Bisphenol A co-exposure effects: a key factor in understanding BPA's complex mechanism and health outcomes.Crit Rev Toxicol. 2019 May;49(5):371-386. doi: 10.1080/10408444.2019.1621263. Epub 2019 Jul 1. Crit Rev Toxicol. 2019. PMID: 31256736 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical